This week is all about Medtronic's blockbuster acquisition of Covidien for nearly $43 billion and the deal's wider implications for medtech; plus, Hill-Rom makes a move in Germany.
LifeScience Alley CEO Shaye Mandle writes that the recently announced marriage of Medtronic and Covidien is a boon for the North Star State.
By: Shaye Mandle, President & CEO, LifeScience Alley
LifeScience Alley, the nation's largest regional life science industry association, welcomes the news that Medtronic, the world’s leading provider of medical technology products, services and solutions, is acquiring Covidien, a leading global healthcare technology and medical supplies provider.
Medtronic's pending $43 billion acquisition of Covidien could trigger 'golden parachute' provisions worth nearly $80 million for Covidien's senior management team.
If the top executives at Covidien decide to leave the company after a $43 billion acquisition by Medtronic goes through, they'll do it under a golden parachute worth a collective $80 million, regulatory filings show.
Medtronic's pending acquisition of Covidien will see the company's headquarters moved to Ireland, and one political hopeful is blaming the Obama Administration for chasing innovation out of the U.S.
The merger of medical device giants Medtronic and Covidien has a range of implications both for those companies and for medtech in general, former Medtronic CEO Bill Hawkins tells MassDevice.com.
By Brad Perriello and Brian Johnson
UPDATED June 16, 2014, with additional comment from Leerink Partners analyst Danielle Antalffy.
Former Medtronic (NYSE:MDT) CEO Bill George says the Covidien (NYSE:COV) deal is about more than inversion in this interview with Squawkbox on MSNBC.
Medtronic makes a big move with its $43 billion deal to acquire Covidien and its string of complementary medical device lines.
Medtronic (NYSE:MDT) said yesterday that it agreed to acquire Covidien (NYSE:COV) in a cash-and-stock deal worth nearly $43 billion.